title: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
abstract: OBJECTIVE
  Previous analyses of the Breast International Group (BIG) 1-98 four-arm study compared initial therapy with letrozole or tamoxifen including patients randomly assigned to sequential treatment whose information was censored at the time of therapy change. Because this presentation may unduly reflect early events, the present analysis is limited to patients randomly assigned to the continuous therapy arms and includes protocol-defined updated results.
  
  
  METHODS
  Four thousand nine hundred twenty-two of the 8,028 postmenopausal women with receptor-positive early breast cancer randomly assigned (double-blind) to the BIG 1-98 trial were assigned to 5 years of continuous adjuvant therapy with either letrozole or tamoxifen; the remainder of women were assigned to receive the agents in sequence. Disease-free survival (DFS) was the primary end point.
  
  
  RESULTS
  At a median follow-up time of 51 months, we observed 352 DFS events among 2,463 women receiving letrozole and 418 events among 2,459 women receiving tamoxifen. This reflected an 18% reduction in the risk of an event (hazard ratio, 0.82; 95% CI, 0.71 to 0.95; P = .007). No predefined subsets showed differential benefit. Adverse events were similar to previous reports. Patients on tamoxifen experienced more thromboembolic events, endometrial pathology, hot flashes, night sweats, and vaginal bleeding. Patients on letrozole experienced more bone fractures, arthralgia, low-grade hypercholesterolemia, and cardiovascular events other than ischemia and cardiac failure.
  
  
  CONCLUSIONS
  The present updated analysis, which was limited to patients on monotherapy arms in BIG 1-98, yields results similar to those from the previous primary analysis but more directly comparable with results from other trials of continuous therapy using a single endocrine agent.
authors.affiliation: International Breast Cancer Study Group (IBCSG), IBCSG Coordinating Center, Bern, Switzerland. alan.coates@ibcsg.org
authors.forename: Alan S
authors.initials: AS
authors.lastname: Coates
authors.forename: Aparna
authors.initials: A
authors.lastname: Keshaviah
authors.forename: Beat
authors.initials: B
authors.lastname: Thürlimann
authors.forename: Henning
authors.initials: H
authors.lastname: Mouridsen
authors.forename: Louis
authors.initials: L
authors.lastname: Mauriac
authors.forename: John F
authors.initials: JF
authors.lastname: Forbes
authors.forename: Robert
authors.initials: R
authors.lastname: Paridaens
authors.forename: Monica
authors.initials: M
authors.lastname: Castiglione-Gertsch
authors.forename: Richard D
authors.initials: RD
authors.lastname: Gelber
authors.forename: Marco
authors.initials: M
authors.lastname: Colleoni
authors.forename: István
authors.initials: I
authors.lastname: Láng
authors.forename: Lucia
authors.initials: L
authors.lastname: Del Mastro
authors.forename: Ian
authors.initials: I
authors.lastname: Smith
authors.forename: Jacquie
authors.initials: J
authors.lastname: Chirgwin
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Nogaret
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Pienkowski
authors.forename: Andrew
authors.initials: A
authors.lastname: Wardley
authors.forename: Erik H
authors.initials: EH
authors.lastname: Jakobsen
authors.forename: Karen N
authors.initials: KN
authors.lastname: Price
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004311:Double-Blind Method; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D000077289:Letrozole; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use*; D017698:Postmenopause; D016016:Proportional Hazards Models; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D009570:Nitriles; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014230:Triazoles; D013629:Tamoxifen; D000077289:Letrozole